Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Immunotherapy for glioblastoma: the promise of combination strategies
Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …
current standard of care involves surgical resection (if possible) followed by concomitant …
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase …
A Omuro, AA Brandes, AF Carpentier, A Idbaih… - Neuro …, 2023 - academic.oup.com
Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …
[HTML][HTML] Single-cell map** of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes
E Friebel, K Kapolou, S Unger, NG Núñez, S Utz… - Cell, 2020 - cell.com
Brain malignancies can either originate from within the CNS (gliomas) or invade from other
locations in the body (metastases). A highly immunosuppressive tumor microenvironment …
locations in the body (metastases). A highly immunosuppressive tumor microenvironment …
Molecular targeted therapy of glioblastoma
E Le Rhun, M Preusser, P Roth, DA Reardon… - Cancer treatment …, 2019 - Elsevier
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …
Current state of immunotherapy for glioblastoma
Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
Macrophages and microglia: the cerberus of glioblastoma
A Buonfiglioli, D Hambardzumyan - Acta neuropathologica …, 2021 - Springer
Glioblastoma (GBM) is the most aggressive and deadliest of the primary brain tumors,
characterized by malignant growth, invasion into the brain parenchyma, and resistance to …
characterized by malignant growth, invasion into the brain parenchyma, and resistance to …
Immunotherapy for glioblastoma: current progress and challenges
MW Yu, DF Quail - Frontiers in immunology, 2021 - frontiersin.org
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15
months when treated with the current standard of care, which consists of surgery …
months when treated with the current standard of care, which consists of surgery …
Multidimensional communication in the microenvirons of glioblastoma
Glioblastomas are heterogeneous and invariably lethal tumours. They are characterized by
genetic and epigenetic variations among tumour cells, which makes the development of …
genetic and epigenetic variations among tumour cells, which makes the development of …
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma (GBM) trials.
Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in …
Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in …